Skip to content

Study · Animal study (in vivo) · rat · 2022

3 results

Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide.

Tyagi P, Koskinen M, Mikkola J, Sarkhel S, Leino L, Seth A, Madalli S, Will S, Howard VG, Brant H, Corkill D

Pharmaceutics2 Mar 2022Cited by 10 (Europe PMC)

PMID35335929 (opens in a new tab)PMCIDPMC8952239 (opens in a new tab)DOI10.3390/pharmaceutics14030553 (opens in a new tab)PepBankPUB-35335929
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Diabetes mellitus is a major healthcare challenge. Pramlintide, a peptide analogue of the hormone amylin, is currently used as an adjunct with insulin for patients who fail to achieve glycemic control with only insulin therapy. However, hypoglycemia is the dominant risk factor associated with such approaches and careful dosing of both drugs is needed. To mitigate this risk factor and compliance issues related to multiple dosing of different drugs, sustained delivery of Pramlintide from silica depot administered subcutaneously (SC) was investigated in a rat model. The pramlintide-silica microparticle hydrogel depot was formulated by spray drying of silica sol-gels. In vitro dissolution tests revealed an initial burst of pramlintide followed by controlled release due to the dissolution of the silica matrix. At higher dosing, pramlintide released from subcutaneously administered silica depot in rats showed a steady concentration of 500 pM in serum for 60 days. Released pramlintide retained its pharmacological activity in vivo, as evidenced by loss of weight. The biodegradable silica matrix offers a sustained release of pramlintide for at least two months in the rat model and shows potential for clinical applications.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, higher-dose pramlintide-silica depot delivery maintained a steady serum pramlintide concentration of 500 pM for 60 days.

    In plain wordsIn rats, a higher-dose pramlintide depot maintained a steady blood concentration for 60 days.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSustained serum concentration
    Study

    ratn: not reported in source

    silica depot delivery in rats
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous · 60 daysAs given in this study (rat).

    Measurements

    Serum pramlintide
    500 pM
    higher-dose subcutaneous silica depot

    Source sentences

    Summary
    At higher dosing, pramlintide released from subcutaneously administered silica depot in rats showed a steady concentration of 500 pM in serum for 60 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, pramlintide released from the silica depot retained biological activity, evidenced by weight loss.

    In plain wordsIn rats, pramlintide released from the silica depot remained active and produced weight loss.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseBody weight
    Study

    ratn: not reported in source

    silica depot delivery in rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Released pramlintide retained its pharmacological activity in vivo, as evidenced by loss of weight.
    1 context sentence
    Summary · context
    To mitigate this risk factor and compliance issues related to multiple dosing of different drugs, sustained delivery of Pramlintide from silica depot administered subcutaneously (SC) was investigated in a rat model.

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 03LabNot a test of Pramlintide (Symlin) aloneIn vitro (cell-free)Pharmacokinetics

    In dissolution tests, the pramlintide-silica depot showed an initial burst followed by controlled release as the silica matrix dissolved.

    In plain wordsIn lab tests, the pramlintide depot released an initial burst, then released peptide gradually as silica dissolved.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableIn vitro release pattern
    Study

    n: not reported in source

    silica microparticle hydrogel depot
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    In vitro dissolution tests revealed an initial burst of pramlintide followed by controlled release due to the dissolution of the silica matrix.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.